X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2024/01/08/2805328/29248/en/Anavex-Life-Sciences-Announces-Grant-of-U-S-Patent-Covering-Blarcamesine-ANAVEX-2-73-for-Treatment-of-Neurodevelopmental-Disorders.html
https://endpts.com/anavexs-experimental-drug-fails-rett-syndrome-study-stock-falls/
https://www.globenewswire.com//news-release/2023/12/19/2798446/29248/en/Anavex-Received-Agreement-from-the-Committee-for-Medicinal-Products-for-Human-Use-CHMP-for-the-Submission-of-a-Marketing-Authorisation-Application-of-Oral-Blarcamesine-for-Alzheime.html
https://www.globenewswire.com//news-release/2023/11/22/2784760/29248/en/Anavex-Life-Sciences-Announces-Grant-of-U-S-Patent-Covering-Blarcamesine-ANAVEX-2-73-for-Treatment-of-Insomnia-or-Anxiety.html
https://www.globenewswire.com/news-release/2023/11/20/2783202/29248/en/Anavex-Initiates-Regulatory-Submission-of-Oral-Blarcamesine-for-Alzheimer-s-Disease-to-European-Medicines-Agency-EMA.html
https://www.globenewswire.com//news-release/2023/09/14/2743153/29248/en/Anavex-s-Phase-2b-3-Trial-of-Blarcamesine-ANAVEX-2-73-in-Patients-with-Alzheimer-s-Disease-Shows-Robust-Clinical-Efficacy-and-Slows-Neurodegeneration.html
https://www.globenewswire.com/news-release/2023/06/28/2696073/29248/en/Long-term-Clinical-Study-Demonstrates-Disease-Modifying-Effects-of-ANAVEX-2-73-blarcamesine-for-Rett-Syndrome.html
https://www.globenewswire.com/news-release/2023/06/06/2682701/29248/en/Anavex-Life-Sciences-Announces-Completion-of-ANAVEX-2-73-blarcamesine-EXCELLENCE-Phase-2-3-Rett-Syndrome-Clinical-Trial.html
https://www.globenewswire.com/news-release/2023/06/01/2680209/29248/en/ANAVEX-Announces-Issuance-of-New-U-S-Intellectual-Property-Compositions-Patent-for-ANAVEX-2-73-blarcamesine.html
https://www.globenewswire.com/news-release/2023/05/01/2658202/29248/en/Anavex-Life-Sciences-Announces-Issuance-of-New-U-S-Patent-Expanding-ANAVEX-2-73-blarcamesine-Intellectual-Property-Portfolio-for-the-Treatment-of-Hypertension.html
https://www.globenewswire.com/news-release/2023/02/02/2600303/29248/en/Anavex-Life-Sciences-Announces-Exceeding-of-Enrollment-Target-for-the-ANAVEX-2-73-blarcamesine-EXCELLENCE-Phase-2-3-Rett-Syndrome-Clinical-Trial.html
https://www.globenewswire.com//news-release/2022/12/02/2566415/29248/en/ANAVEX-2-73-Blarcamesine-Phase-2B-3-Study-Met-Primary-and-Key-Secondary-Endpoints-Showing-Statistically-Significant-Reduction-of-Clinical-Decline-in-Global-Clinical-Study-of-Patien.html
https://www.globenewswire.com/news-release/2022/10/17/2535302/29248/en/Anavex-Life-Sciences-Announces-Late-Breaking-Presentation-of-Phase-2b-3-Data-of-Oral-ANAVEX-2-73-blarcamesine-for-Early-Alzheimer-s-Disease-at-the-Upcoming-Clinical-Trials-on-Alzhe.html
https://www.globenewswire.com/news-release/2022/09/21/2520021/29248/en/Anavex-Life-Sciences-Announces-Issuance-of-U-S-Patent-Covering-ANAVEX-2-73-blarcamesine-for-Neurodevelopmental-Disorders-Therapy.html
https://www.globenewswire.com/news-release/2022/02/04/2379201/29248/en/Anavex-Life-Sciences-Provides-Supplemental-Information-on-ANAVEX-2-73-Blarcamesine-AVATAR-Phase-3-Trial-for-the-Treatment-of-Adult-Patients-with-Rett-Syndrome.html
https://www.fiercebiotech.com/biotech/anavex-touts-very-large-phase-3-win-for-rett-syndrome-drug-2-weeks-after-moving-study-s
https://www.globenewswire.com/news-release/2021/06/21/2250100/29248/en/Anavex-Life-Sciences-Announces-ANAVEX-2-73-Blarcamesine-Biomarker-Correlated-with-Efficacy-Endpoints-in-Placebo-Controlled-U-S-Phase-2-Clinical-Trial-for-the-Treatment-of-Adult-Pat.html
https://www.globenewswire.com/news-release/2021/06/14/2246382/29248/en/Anavex-Life-Sciences-Reports-New-Publication-in-Medical-Journal-Elucidating-the-Mechanism-of-ANAVEX-2-73-blarcamesine-and-ANAVEX-3-71-AF710B-related-to-the-Treatment-of-Alzheimer-s.html
https://www.globenewswire.com/news-release/2020/12/15/2145200/0/en/Anavex-Life-Sciences-Announces-ANAVEX-2-73-Blarcamesine-Meets-Primary-and-Secondary-Endpoints-in-Placebo-Controlled-U-S-Phase-2-Clinical-Trial-for-the-Treatment-of-Adult-Patients-w.html
https://www.globenewswire.com/news-release/2020/11/30/2136362/0/en/Anavex-Life-Sciences-Announces-Notice-of-Allowance-for-U-S-Patent-Application-with-Expanding-Claims-Covering-ANAVEX-2-73-blarcamesine-for-the-Treatment-of-Rett-Syndrome-and-other-N.html
https://www.globenewswire.com/news-release/2020/11/06/2122133/0/en/Homology-Medicines-Announces-Presentation-of-Positive-Data-from-the-Dose-Escalation-Phase-of-the-pheNIX-Gene-Therapy-Trial-for-Adults-with-PKU.html
https://www.globenewswire.com/news-release/2020/10/15/2109061/0/en/Anavex-Life-Sciences-Announces-Positive-Results-from-Proof-of-Concept-controlled-Phase-2-Clinical-Trial-Evaluating-ANAVEX-2-73-blarcamesine-in-Parkinson-s-Disease-Dementia.html
https://seekingalpha.com/news/3612834-anavex-completes-mid-stage-study-of-lead-drug-in-rare-brain-development-disorder
https://www.anavex.com/anavex-life-sciences-receives-tga-special-access-scheme-approval-for-anavex2-73-blarcamesine-for-alzheimers-disease-patients/
https://www.clinicaltrialsarena.com/news/anavex-rett-syndrome-trial/
http://www.globenewswire.com/news-release/2020/07/01/2056105/0/en/Anavex-Life-Sciences-Announces-First-Patient-Dosed-in-EXCELLENCE-Phase-2-3-Clinical-Trial-of-ANAVEX-2-73-Blarcamesine-in-Patients-with-Rett-Syndrome.html
https://www.globenewswire.com/news-release/2020/06/16/2048640/0/en/Anavex-Life-Sciences-Announces-Exceeding-of-Enrollment-Target-for-the-ANAVEX-2-73-blarcamesine-U-S-Phase-2-Rett-Syndrome-Clinical-Trial.html
https://www.globenewswire.com/news-release/2020/06/04/2043583/0/en/Anavex-Life-Sciences-Receives-Regulatory-Approval-from-Health-Canada-and-UK-MHRA-Expanding-Phase-2b-3-ANAVEX-2-73-blarcamesine-into-Multinational-Clinical-Trial-for-Alzheimer-s-Dis.html
https://www.globenewswire.com/news-release/2020/05/21/2036906/0/en/Anavex-Life-Sciences-Announces-Initiation-of-First-in-Human-Phase-1-Study-of-ANAVEX-3-71-AF710B.html
https://www.globenewswire.com/news-release/2020/04/23/2020772/0/en/Anavex-Life-Sciences-Announces-Publication-of-Clinical-Data-for-ANAVEX-2-73-blarcamesine-in-Alzheimer-s-Disease.html
https://www.globenewswire.com/news-release/2020/02/24/1989102/0/en/Anavex-Life-Sciences-Announces-Publication-of-Foundational-Data-for-ANAVEX-2-73-blarcamesine-in-Multiple-Sclerosis-MS.html
https://www.globenewswire.com/news-release/2020/02/03/1978618/0/en/Anavex-Life-Sciences-Announces-Fast-Track-Designation-Granted-by-U-S-FDA-for-ANAVEX-2-73-blarcamesine-Clinical-Development-Program-for-the-Treatment-of-Rett-Syndrome.html
https://www.globenewswire.com/news-release/2020/01/27/1975326/0/en/Anavex-Life-Sciences-Announces-Achievement-of-Enrollment-Target-for-the-ANAVEX-2-73-blarcamesine-Phase-2-Parkinson-s-Disease-Dementia-PDD-Clinical-Trial.html
https://www.anavex.com/anavex-life-sciences-presents-anavex2-73-blarcamesine-data-at-12th-clinical-trials-on-alzheimers-disease-ctad-2019-conference/
Market Place
Share 
